Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC 55-0414 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| NNC 55-0414 | DRUG | - |
Inclusion Criteria: * Type 2 diabetes * Diet treatment only for at least two weeks * Body mass index (BMI) between 22-34 kg/m2 inclusive * HbA1C between 6.5-12.0% inclusive * Fasting blood glucose (FBG) between 7.0-18.0 mmol/L inclusive * Patients should be negative (lesser than 70 kU/l) for antibo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC 55-0414 is an investigational small molecule being developed for the treatment of type 2 diabetes. It is intended for use in subjects with diabetes, specifically type 2 diabetes mellitus. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NNC 55-0414 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical research on this investigational drug for the treatment of type 2 diabetes.
NNC 55-0414 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied for its effects in subjects with type 2 diabetes, and its clinical trial has been completed.
NNC 55-0414 has been studied in a Phase 1 clinical trial registered as NCT00400283, titled "A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes." This trial was completed and enrolled 23 participants in Germany, with a minimum age of 40 years.
The specific mechanism of action of NNC 55-0414 has not been disclosed in available information. It is a small molecule being investigated for its potential to treat type 2 diabetes, but its molecular target and mode of action are not publicly detailed.